ESR1 and breast cancer: rs2981582 in the FGFR2 locus was significantly associated with ER+/PR+/HER2- breast cancer (ncases=7201, p = 2.2 × 10−29), less so with ER+/PR+/HER2+ cases (ncases=996, p=5.5×10−4), and no association was observed with triple negative breast cancer (ncases=1480, p=0.841) or ER-/PR-/HER2+ breast cancer (ncases=627, p=0.396).